NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
Incyte Corporation
Eli Lilly and Company
Actuate Therapeutics Inc.
Novo Nordisk A/S
Leaf Vertical Inc.